Form 4: Avidity CEO Sells All Shares in Novartis Merger

Avidity Biosciences' President and CEO, Sarah Boyce, disposed of all her common stock and stock options as part of the acquisition by Novartis AG.

Summary

• Sarah Boyce, President and CEO, and a Director of Avidity Biosciences, Inc., reported the disposition of all her beneficial ownership in the company.
• This transaction occurred on February 27, 2026, pursuant to the Agreement and Plan of Merger dated October 25, 2025, with Novartis AG.
• Boyce disposed of 474,861 shares of Common Stock.
• She also disposed of multiple tranches of stock options, totaling 2,176,015 options, in exchange for a cash payment.
• The cash payment for options was calculated as the merger consideration of $72.00 per share minus the respective exercise price of each option.
• Following these transactions, Boyce holds zero beneficial ownership in Avidity Biosciences, Inc.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive event for the reporting person, as it represents a successful monetization of their equity holdings at a pre-determined merger price, indicating a favorable outcome for Avidity shareholders involved in the acquisition.

Positives

• The reporting person received a significant cash payment for her shares and in-the-money stock options due to the merger.
• The merger consideration of $72.00 per share represents a clear valuation for the company's equity.

Negatives

• The reporting person no longer holds any direct or indirect beneficial ownership in Avidity Biosciences, Inc.
• The company is being acquired, indicating a loss of independence for Avidity Biosciences.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that the acquisition of Avidity Biosciences by Novartis AG signifies continued consolidation within the biotechnology and pharmaceutical sectors, particularly for companies with promising RNA-based therapeutic platforms. This trend often reflects larger pharmaceutical companies seeking to bolster their pipelines with innovative technologies and de-risked assets.

Comparison to Industry Standards

• The merger consideration of $72.00 per share for Avidity Biosciences (RNAM) can be assessed against recent biotech acquisitions. For instance, Pfizer's acquisition of Seagen for $43 billion (approximately $229 per share) in 2023, or Merck's acquisition of Prometheus Biosciences for $10.8 billion (approximately $200 per share) in 2023, involved significantly higher per-share values, reflecting different stages of development, pipeline strength, and market capitalization. While a direct comparison is complex due to varying company specifics, the $72.00 per share for Avidity suggests a valuation that was deemed attractive by Novartis, potentially reflecting Avidity's specific therapeutic focus and clinical progress in RNA-targeting therapies.

Stakeholder Impact

• Shareholders: Existing shareholders of Avidity Biosciences would have received the $72.00 per share merger consideration.
• Employees: Employees of Avidity Biosciences will likely be integrated into Novartis AG, potentially impacting roles, benefits, and corporate culture.
• Management: The reporting person, as President and CEO, has monetized her equity, and her future role within the combined entity is not detailed but implied to change given the acquisition.

Next Steps

• Completion of the merger process between Avidity Biosciences, Inc. and Novartis AG.
• Integration of Avidity Biosciences' operations and assets into Novartis AG.

Key Dates

Recommendation

The recommendation is 'hold' because the company is being acquired, and the merger consideration of $72.00 per share has already been established. There is no further upside potential for Avidity Biosciences' stock price beyond the merger price, and any remaining trading would likely be arbitrage-driven until the final closing. Investors who have not yet tendered their shares would hold until the merger completes to receive the cash consideration.

Keywords

Avidity Biosciences, RNAM, Novartis AG, Merger, Acquisition, Form 4, Insider Trading, Stock Options, Common Stock, Sarah Boyce, Biotechnology, Pharmaceuticals